Around the Practice: Updates in Treating HER2+ Breast Cancer

Sara A. Hurvitz, MD, briefly describes the treatment landscape for HER2+ breast cancer and the panelists take an in-depth look at the data from the DESTINY-Breast03 trial.

Experts discuss the use of trastuzumab-deruxtecan (T-DXd) in clinical practice.

The panel analyzes the data from DESTINY-Breast03 and DESTINY-Breast01 and how these data will further impact practice.

Reshma Mahtani, DO, and Neil Iyengar, MD, discuss the data presented at ESMO 2021 in the TUXEDO-1 and HER2CLIMB-04 trials.

Our panel of experts review the latest data on the antibody drug conjugate, trastuzumab duocarmazine.

Reshma Mahtani, DO, discusses considerations for use of trastuzumab duocarmazine in HER2+ breast cancer.

Patient Case 1 is presented to the panel, and Vijayakrishna Gadi, MD, PhD, shares his thoughts on how to approach treatment of this patient.

Patient Case 2 is presented, and Dr Gadi and Dr Mahtani detail how they would proceed with treating this patient.

The panelists share their insights on managing toxicities and special considerations in the treatment of HER2+ breast cancer.

Experts provide clinical pearls to the audience on treating patients with breast cancer.

A panel of experts led by Sara Hurvitz, MD, discuss recent data within the HER2-positive breast cancer treatment landscape.